Question 1

What dose of CBD is effective for anxiety?

Accepted Answer

Clinical trials demonstrating anxiolytic effects have used single doses of 300–600mg CBD. This is substantially higher than the 10–50mg found in most commercial CBD products. A 2019 RCT (Masataka, Frontiers in Psychology) found 300mg effective for social anxiety in a public speaking test. The 2011 Crippa et al. fMRI study used 400mg. Chronic dosing studies are limited — most evidence is from single-dose paradigms. The clinical relevance of low-dose commercial CBD for anxiety remains unestablished. For context, Epidiolex (FDA-approved CBD) is dosed at 5–20mg/kg/day for epilepsy, which translates to 350–1,400mg/day for a 70kg adult.

Question 2

How does THC reduce pain at the molecular level?

Accepted Answer

THC reduces pain through multiple mechanisms. Primary: partial agonism at CB1 receptors in the dorsal horn of the spinal cord inhibits nociceptive signal transmission by reducing presynaptic glutamate and substance P release. Secondary: CB1 activation in the periaqueductal gray (PAG) activates descending inhibitory pathways. Peripheral CB1 and CB2 receptors on nociceptors reduce peripheral sensitization. THC also activates TRPV1 channels (causing initial activation then desensitization) and modulates opioid receptor signaling. The analgesic effect is dose-dependent and subject to tolerance via CB1 receptor downregulation with chronic use.

Question 3

Why does cannabis suppress REM sleep, and does it matter?

Accepted Answer

THC suppresses REM sleep through CB1 receptor activation in the brainstem reticular formation, particularly the pedunculopontine tegmental (PPT) nucleus, which is critical for REM generation. This reduces both REM duration and density in a dose-dependent manner. Whether this matters clinically is debated. REM sleep is important for emotional memory consolidation and threat extinction — processes relevant to PTSD and anxiety. Chronic REM suppression in animal models impairs fear extinction learning. In humans, long-term heavy users show altered emotional processing. However, for patients whose sleep is severely disrupted by pain or PTSD nightmares, short-term REM suppression may be an acceptable trade-off. Rebound REM (vivid dreams, nightmares) occurs for 1–3 weeks after cessation.

Question 4

How does CBD reduce seizures — what are the mechanisms?

Accepted Answer

CBD's anticonvulsant mechanisms are distinct from its anxiolytic effects and involve multiple molecular targets: (1) GPR55 antagonism — GPR55 is a putative cannabinoid receptor whose activation promotes neuronal excitability; CBD blocks it. (2) TRPV1 desensitization — reduces neuronal hyperexcitability. (3) Voltage-gated sodium channel modulation — CBD inhibits persistent sodium currents that drive repetitive firing. (4) Adenosine reuptake inhibition — increases extracellular adenosine, which has anticonvulsant effects via A1 receptors. (5) Modulation of intracellular calcium signaling. Notably, CB1 receptor agonism does not appear to be the primary anticonvulsant mechanism, which is why CBD works without psychoactive effects. The relative contribution of each mechanism varies by seizure type.

Question 5

Can cannabis kill cancer cells? What does the research actually show?

Accepted Answer

Cannabinoids do kill cancer cells in laboratory settings — this is well-established in preclinical research. The mechanisms include: induction of apoptosis via ceramide synthesis and ER stress; inhibition of angiogenesis (tumor blood vessel formation); reduction of tumor cell migration and invasion; and autophagy induction. These effects have been demonstrated across glioblastoma, breast, prostate, colorectal, and lung cancer cell lines. However, three critical caveats apply: (1) The concentrations required (typically 5–20μM) are far higher than achievable in human plasma with any practical dosing regimen. (2) Some studies show paradoxical pro-tumor effects at lower, clinically relevant concentrations — particularly via CB2-mediated immunosuppression. (3) Zero human RCTs have demonstrated anti-tumor efficacy. The gap between cell-line results and human outcomes is enormous. Patients should not use cannabis as a cancer treatment or delay proven therapies based on this preclinical data.

Question 6

Which medications interact dangerously with CBD?

Accepted Answer

CBD is a potent inhibitor of CYP2C19 and CYP3A4 liver enzymes, and a moderate inhibitor of CYP2D6. The most clinically significant interactions: (1) Clobazam — CBD inhibits CYP2C19, increasing the active metabolite N-desmethylclobazam by 3–5x, causing sedation and respiratory depression. Dose reduction required. (2) Warfarin — CBD increases warfarin levels via CYP2C9 inhibition; INR can rise dangerously. Close monitoring required. (3) Tacrolimus and cyclosporine — immunosuppressant levels increase significantly; transplant rejection or toxicity risk. (4) Valproate — pharmacodynamic interaction causing elevated liver enzymes (additive hepatotoxicity). (5) Rifampin — a CYP inducer that dramatically reduces CBD levels. (6) Many antiepileptics, antidepressants, and antipsychotics are metabolized by these enzymes. Always consult a pharmacist before combining CBD with any prescription medication.

Question 7

Does cannabis use during adolescence cause permanent brain damage?

Accepted Answer

The evidence supports lasting — but not necessarily permanent — cognitive effects from heavy adolescent cannabis use. The Dunedin cohort study (Meier et al., PNAS 2012, n=1,037) found that persistent cannabis use starting before age 18 was associated with an 8-point IQ decline by age 38, not fully reversed by cessation. However, a Norwegian twin study suggested socioeconomic confounding. More recent neuroimaging studies show structural differences in prefrontal cortex, hippocampus, and amygdala in adolescent-onset heavy users. Mechanistically, the adolescent brain undergoes critical CB1 receptor-dependent synaptic pruning — THC disrupts this process. Key nuances: (1) Effects are dose-dependent — light/occasional use shows minimal long-term impairment. (2) Age of onset matters — before 16 is higher risk than 16–18. (3) "Permanent" is an overstatement for most users; significant recovery occurs with sustained abstinence. (4) Adult-onset heavy use shows much smaller cognitive effects.

Question 8

Why is oral CBD so poorly absorbed, and how can absorption be improved?

Accepted Answer

Oral CBD has only ~6% bioavailability due to extensive first-pass hepatic metabolism — primarily by CYP3A4 and CYP2C19 — and poor aqueous solubility (CBD is highly lipophilic, logP ~6.3). Most orally ingested CBD is metabolized to 7-hydroxy-CBD and 7-carboxy-CBD before reaching systemic circulation. Strategies to improve absorption: (1) High-fat meals — a high-fat meal increases CBD Cmax by ~5x and AUC by ~4x (FDA data from Epidiolex trials). (2) Sublingual administration — bypasses first-pass metabolism, achieving 35% higher Cmax with faster onset (~45 min vs. 2+ hours). (3) Lipid-based formulations — self-emulsifying drug delivery systems (SEDDS) improve solubilization. (4) Nanoformulations — nanoemulsions and liposomal CBD show improved bioavailability in early studies. (5) Inhalation — 10–35% bioavailability with rapid onset, but respiratory risks. For therapeutic use, sublingual or oral-with-fat is the most practical improvement over standard oral dosing.

Question 9

Does cannabis cause psychosis or schizophrenia?

Accepted Answer

Cannabis use is associated with increased risk of psychosis, but the relationship is complex and not simply causal. Key findings: (1) Meta-analyses find cannabis users have ~2x increased risk of psychotic disorders vs. non-users; daily high-potency (>10% THC) users have ~5x risk. (2) The association is dose-dependent — frequency, potency, and age of onset all matter. (3) Genetic vulnerability is critical — individuals with COMT Val158Met polymorphism or family history of psychosis are at substantially higher risk. (4) CBD appears to counteract THC-induced psychotomimetic effects — high-CBD strains are associated with lower psychosis risk than high-THC strains. (5) Causality vs. self-medication: some individuals with prodromal psychosis use cannabis to manage symptoms, inflating the association. The current scientific consensus (including NIDA and WHO) is that cannabis can precipitate psychosis in genetically vulnerable individuals and worsen outcomes in those with established schizophrenia, but does not cause schizophrenia in the general population.

Question 10

Is clinical endocannabinoid deficiency (CECD) a real condition?

Accepted Answer

Clinical endocannabinoid deficiency (CECD) is a hypothesis proposed by Dr. Ethan Russo (2004, 2016) suggesting that conditions like migraine, fibromyalgia, and IBS may result from deficient endocannabinoid tone. The hypothesis has biological plausibility: (1) Migraine patients show lower CSF anandamide levels than controls. (2) Fibromyalgia patients show altered CB1 receptor expression. (3) All three conditions respond to treatments that enhance endocannabinoid signaling. However, CECD is not an established medical diagnosis. The evidence is largely indirect and correlational. No validated biomarker exists for endocannabinoid deficiency. The hypothesis is scientifically interesting and has generated useful research questions, but should not be used to justify cannabis treatment for these conditions without direct clinical evidence. It remains a hypothesis, not a confirmed pathophysiological mechanism.

Question 11

What is the optimal THC:CBD ratio for medical use?

Accepted Answer

There is no single "optimal" ratio — the evidence suggests different ratios are appropriate for different conditions. What the research shows: (1) For cancer pain: balanced 1:1 THC:CBD (nabiximols/Sativex) outperforms THC-only in RCTs, with fewer adverse effects. The CBD appears to modulate THC's psychoactive effects via CB1 negative allosteric modulation. (2) For epilepsy: high-CBD, low-THC (Epidiolex is pure CBD). THC can actually lower seizure threshold in some epilepsy types. (3) For anxiety: high-CBD, low-THC. THC worsens anxiety at higher doses; CBD is anxiolytic. (4) For sleep onset: moderate THC may be more effective than CBD alone for acute sleep latency reduction. (5) For nausea: THC is the primary antiemetic; CBD adds limited benefit. The entourage effect hypothesis suggests whole-plant preparations may outperform isolates, but clinical evidence is limited. Practically, patients should start with high-CBD, low-THC ratios and titrate THC upward based on response and tolerability.

Question 12

Is cannabis safe to use during pregnancy?

Accepted Answer

No. Current evidence does not support cannabis use during pregnancy, and most medical organizations (ACOG, AAP, CDC) recommend complete abstinence. Key findings: (1) THC crosses the placenta and blood-brain barrier of the fetus. (2) CB1 receptors are expressed early in fetal neurodevelopment and play critical roles in neuronal migration and synaptogenesis. (3) Prenatal cannabis exposure is associated with lower birth weight, preterm birth, and increased NICU admission in multiple large cohort studies. (4) Longitudinal studies (Ottawa Prenatal Prospective Study, ABCD Study) show associations with cognitive deficits, attention problems, and increased anxiety in children exposed prenatally. (5) CBD is not established as safe in pregnancy — it is metabolized to THC in vivo and has not been studied in pregnant humans. The FDA explicitly warns against CBD use in pregnancy. The "morning sickness" use case is particularly concerning given the developmental vulnerability of early pregnancy.

Question 13

How does CBD reduce inflammation?

Accepted Answer

CBD reduces inflammation through multiple mechanisms: (1) inhibition of adenosine reuptake, increasing extracellular adenosine which suppresses inflammatory cytokines via A2A receptors; (2) activation of TRPV1 channels, which desensitizes pain and inflammatory signaling; (3) indirect modulation of CB2 receptors on immune cells, reducing macrophage and microglial activation; (4) inhibition of NF-κB signaling, a master regulator of inflammatory gene expression; and (5) activation of PPARγ, a nuclear receptor with broad anti-inflammatory effects. Unlike THC, CBD does not directly bind CB1 or CB2 receptors with high affinity, explaining its lack of psychoactivity while retaining anti-inflammatory properties. Most evidence comes from preclinical models; robust human RCT data for inflammatory conditions remain limited.

Question 14

Does THC suppress the immune system?

Accepted Answer

THC has immunosuppressive effects, primarily mediated through CB2 receptors on immune cells. In vitro and animal studies show THC reduces T-cell proliferation, suppresses natural killer cell activity, inhibits macrophage function, and shifts cytokine profiles toward anti-inflammatory (Th2) patterns. In humans, chronic cannabis users show altered immune profiles, though the clinical significance is debated. For most healthy adults, these effects appear modest and reversible. However, for immunocompromised patients (HIV, transplant recipients, cancer patients on chemotherapy), the immunosuppressive effects may be clinically relevant. Paradoxically, this immunosuppression is also the basis for investigating cannabinoids in autoimmune conditions.

Question 15

Can cannabis help with autoimmune diseases like rheumatoid arthritis or lupus?

Accepted Answer

The evidence for cannabis in autoimmune diseases is promising but limited. For rheumatoid arthritis, a 2006 RCT of nabiximols (THC:CBD) showed significant reductions in pain and disease activity scores vs. placebo — the only RCT in RA to date. For multiple sclerosis, nabiximols is approved in multiple countries for spasticity, with robust RCT evidence. For lupus, IBD, and psoriasis, evidence is primarily observational or preclinical. The theoretical basis is strong — CB2 receptors are densely expressed on immune cells, and cannabinoids modulate the cytokine profiles implicated in autoimmune pathology. However, the immunosuppressive effects of THC raise concerns about infection risk, and CBD's clinical evidence in autoimmune conditions lags behind its preclinical promise.

Question 16

Is CBG more anti-inflammatory than CBD?

Accepted Answer

Preclinical evidence suggests CBG may have potent anti-inflammatory properties, potentially comparable to or exceeding CBD in some models. CBG acts as a partial agonist at CB2 receptors (which are highly expressed on immune cells) and also inhibits COX-1 and COX-2 enzymes — the same targets as NSAIDs like ibuprofen. In mouse models of inflammatory bowel disease, CBG reduced colon weight, nitric oxide production, and inflammatory cytokines. CBG also activates α2-adrenoceptors, which have anti-inflammatory effects in the gut. However, direct head-to-head comparisons with CBD in human trials do not exist. CBG research is approximately 10 years behind CBD, and all current anti-inflammatory evidence is preclinical.

Question 17

What is the correct dose of CBD for most conditions?

Accepted Answer

There is no single "correct" CBD dose — effective doses vary dramatically by condition, individual pharmacokinetics, and route of administration. The only FDA-approved CBD (Epidiolex) is dosed at 5–20mg/kg/day for epilepsy, translating to 350–1,400mg/day for a 70kg adult. For anxiety, RCTs have used single doses of 300–600mg. For sleep, doses of 25–175mg have been studied. Most commercial CBD products contain 10–50mg per serving — substantially below doses showing efficacy in clinical trials. Oral bioavailability of CBD is only 6–19%, meaning much of an oral dose is lost to first-pass metabolism. Sublingual administration improves bioavailability modestly. The gap between commercial product doses and clinically effective doses is one of the most important and underreported issues in CBD research.

Question 18

What is THC microdosing and does it work?

Accepted Answer

THC microdosing refers to using sub-intoxicating doses of THC (typically 1–5mg) to achieve therapeutic effects without psychoactive impairment. The theoretical basis is the biphasic dose-response of THC: low doses may reduce anxiety, pain, and nausea while high doses worsen anxiety and impair cognition. A 2022 study (Cuttler et al.) found that 7.5mg THC reduced stress more effectively than placebo, while 12.5mg increased negative affect. For pain, a 2015 crossover trial found that low-dose vaporized cannabis (1.29% THC) reduced neuropathic pain more effectively than medium or high doses. However, most microdosing research is preliminary, and individual variation in THC sensitivity (driven by CYP2C9 genetics and CB1 receptor density) makes universal dosing recommendations impossible.

Question 19

What is the difference between oral and inhaled cannabis in terms of effects and duration?

Accepted Answer

Route of administration profoundly affects cannabis pharmacokinetics. Inhaled cannabis (smoked or vaporized): onset 2–10 minutes, peak effects 20–30 minutes, duration 2–3 hours. THC bioavailability is 10–35% via inhalation. Oral cannabis (edibles, capsules): onset 30–120 minutes, peak effects 2–4 hours, duration 4–8 hours. Oral bioavailability is only 4–20% due to first-pass metabolism, but the liver converts THC to 11-hydroxy-THC, which is more potent and longer-lasting than THC itself — explaining why edibles often produce stronger, more prolonged effects than expected. Sublingual (tinctures): intermediate onset (15–45 minutes), moderate bioavailability. The delayed onset of oral cannabis is the primary cause of accidental overconsumption, as users re-dose before the first dose takes effect.

Question 20

How quickly does tolerance to cannabis develop, and does it reverse?

Accepted Answer

Tolerance to THC's psychoactive and some therapeutic effects develops rapidly with regular use. CB1 receptor downregulation and desensitization begin within days of daily use. PET imaging studies show CB1 receptor density decreases by 15–20% after 4 weeks of daily cannabis use. Tolerance to antiemetic effects appears to develop more slowly than tolerance to euphoria. Tolerance reverses with abstinence — CB1 receptor density returns to near-baseline within 4 weeks of cessation in most studies. Tolerance to CBD is less well-characterized; animal studies suggest minimal tolerance development, which may explain why Epidiolex maintains efficacy long-term. Cross-tolerance between THC and synthetic cannabinoids (dronabinol, nabilone) is well-documented.

Question 21

Does CBD interact with warfarin (blood thinners)?

Accepted Answer

Yes — CBD has a clinically significant interaction with warfarin. CBD inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism. This inhibition increases warfarin blood levels, potentially raising INR (international normalized ratio) and bleeding risk. Multiple case reports document INR elevation in patients who added CBD to stable warfarin regimens. In one case series, INR increased from therapeutic range (2–3) to supratherapeutic levels (>4) within weeks of starting CBD. The interaction is dose-dependent and more pronounced at higher CBD doses. Patients on warfarin who use CBD require more frequent INR monitoring and likely warfarin dose reduction. This interaction extends to other CYP2C9 substrates including phenytoin, losartan, and some NSAIDs.

Question 22

Is it safe to use cannabis with antidepressants?

Accepted Answer

Cannabis interactions with antidepressants are complex and vary by drug class. SSRIs/SNRIs: CBD inhibits CYP2D6 and CYP3A4, which metabolize many SSRIs (fluoxetine, paroxetine) and SNRIs. This can increase antidepressant blood levels and side effects. THC may also interact pharmacodynamically, potentially worsening anxiety or triggering mania in susceptible individuals. MAOIs: Potentially dangerous combination — both cannabis and MAOIs affect serotonin systems; risk of serotonin syndrome is theoretical but not well-characterized. TCAs: CBD inhibits CYP2D6, which metabolizes tricyclics; elevated TCA levels increase cardiac arrhythmia risk. Bupropion: Both THC and bupropion lower seizure threshold; combination may increase seizure risk. The safest approach is to consult a prescribing physician before combining cannabis with any antidepressant.

Question 23

Can cannabis reduce opioid requirements for pain?

Accepted Answer

Observational evidence consistently shows that medical cannabis patients reduce opioid consumption, but RCT evidence is limited. A 2016 systematic review found that 64–79% of medical cannabis patients reported reduced opioid use. A 2019 prospective study of 1,514 patients found a 44% reduction in opioid use after 6 months of medical cannabis. Mechanistically, cannabinoids and opioids act on different but complementary pain pathways — CB1 and opioid receptors are co-expressed in pain-processing regions and show synergistic analgesia in animal models. However, no RCT has directly tested cannabis as an opioid substitute. Pharmacokinetically, CBD inhibits CYP3A4, which metabolizes many opioids, potentially increasing opioid blood levels. The combination requires careful monitoring.

Question 24

What are the symptoms of cannabis withdrawal?

Accepted Answer

Cannabis withdrawal syndrome (CWS) is a recognized clinical entity in DSM-5. It occurs in approximately 47% of regular cannabis users who stop abruptly. Symptoms typically begin 24–72 hours after cessation, peak at days 2–6, and resolve within 2–3 weeks. Common symptoms include: irritability, anxiety, and agitation (most common, ~75% of cases); sleep disturbance and insomnia; decreased appetite and weight loss; restlessness; depressed mood; physical symptoms including headache, sweating, chills, and stomach pain. Severity correlates with frequency and duration of use, and potency of cannabis used. Withdrawal is rarely medically dangerous but is a major driver of relapse. No FDA-approved pharmacotherapy exists specifically for CWS, though gabapentin, zolpidem, and CBD have shown promise in small trials.

Question 25

How addictive is cannabis compared to other drugs?

Accepted Answer

Cannabis has a lower addiction potential than most other commonly used substances, but it is not non-addictive. Approximately 9% of people who ever use cannabis develop cannabis use disorder (CUD), compared to 15% for alcohol, 17% for cocaine, 23% for heroin, and 32% for nicotine. Risk is substantially higher for those who begin in adolescence (17%) and daily users (25–50%). The addictive potential has likely increased as average THC potency has risen from ~4% in the 1990s to 12–20%+ in current products. Cannabis does not produce the severe physical withdrawal of opioids or alcohol, but psychological dependence and craving are well-documented. The dopaminergic reward pathway is activated by THC via CB1 receptors in the nucleus accumbens — the same mechanism underlying other addictive substances.

Question 26

Can CBD help treat addiction to other substances?

Accepted Answer

CBD is being actively investigated as a treatment for multiple substance use disorders. For opioid addiction: a 2019 RCT (Hurd et al., American Journal of Psychiatry) found CBD 400–800mg/day significantly reduced cue-induced craving and anxiety in heroin-abstinent individuals — the most rigorous evidence to date. For cannabis use disorder: CBD has shown promise in reducing cannabis use and withdrawal symptoms in small trials. For alcohol use disorder: preclinical evidence is strong (CBD reduces alcohol intake in animal models), but human RCT data are limited. For tobacco: a 2013 pilot RCT found CBD inhaler reduced cigarette consumption by 40% vs. placebo. The mechanisms likely involve CBD's effects on stress reactivity, anxiety, and cue-induced craving via 5-HT1A and TRPV1 pathways.

Question 27

Is cannabis a gateway drug?

Accepted Answer

The "gateway drug" hypothesis — that cannabis use leads to harder drug use — is one of the most debated topics in addiction science. The evidence shows: (1) Most cannabis users do not progress to harder drugs. (2) There is a statistical association between cannabis use and subsequent use of other substances, but correlation does not imply causation. (3) The same risk factors (genetics, trauma, peer environment, mental health) that predispose to cannabis use also predispose to other substance use. (4) Animal studies show THC exposure during adolescence increases sensitivity to opioids and cocaine, suggesting a neurobiological mechanism. (5) In jurisdictions that have legalized cannabis, rates of other drug use have not consistently increased. The current scientific consensus is that cannabis is not a pharmacological gateway drug, but it may be a social or behavioral gateway in some contexts.

Question 28

Can you overdose on cannabis? What is the lethal dose?

Accepted Answer

A fatal overdose from cannabis alone has never been documented in humans. The estimated lethal dose of THC in humans (extrapolated from animal data) is approximately 1,260mg/kg body weight — for a 70kg adult, this would be roughly 88 grams of pure THC, an amount impossible to consume in a single session. However, "overdose" in the clinical sense (requiring medical attention) does occur. Cannabis overconsumption causes cannabinoid hyperemesis syndrome, severe anxiety and panic attacks, psychosis-like episodes, tachycardia, and in rare cases, cannabis-induced psychosis requiring hospitalization. Edibles are the most common cause of overconsumption due to delayed onset. Synthetic cannabinoids ("spice," "K2") are far more dangerous and have caused deaths. Cannabis use is also associated with increased accident risk (driving, falls) and cardiovascular events in susceptible individuals.

Question 29

How does cannabis affect driving ability?

Accepted Answer

Cannabis impairs driving ability, though the magnitude and duration of impairment differ from alcohol. THC impairs: reaction time, divided attention, lane tracking, and speed regulation. Meta-analyses show cannabis approximately doubles the risk of a motor vehicle accident. Impairment is most pronounced in the first 1–3 hours after use and correlates with blood THC levels, though the relationship is less predictable than for alcohol. Unlike alcohol, blood THC levels are a poor proxy for impairment — THC is detectable in blood for days to weeks after use in regular users, long after impairment has resolved. CBD does not appear to impair driving at therapeutic doses. Combining cannabis with alcohol produces additive impairment greater than either alone. Most jurisdictions have per se THC limits for driving (typically 2–5 ng/mL blood THC), though these thresholds are scientifically contested.

Question 30

Does cannabis cause mental illness?

Accepted Answer

Cannabis use is associated with increased risk of psychosis, schizophrenia, depression, and anxiety disorders, but the causal relationship is complex. For psychosis: the evidence is strongest. A 2019 Lancet Psychiatry study found daily high-potency cannabis use was associated with a 5-fold increased risk of psychosis. The risk is dose-dependent, potency-dependent, and substantially higher in those with genetic predisposition (COMT Val158Met polymorphism). For schizophrenia: cannabis use is associated with earlier onset and worse outcomes, but whether it causes schizophrenia in those without predisposition remains debated. For depression and anxiety: associations exist but causality is unclear — people with depression and anxiety may self-medicate with cannabis. The adolescent brain appears particularly vulnerable; cannabis use before age 16 is associated with substantially higher mental health risks than adult-onset use.

Question 31

Does smoking cannabis damage the lungs?

Accepted Answer

Smoking cannabis causes respiratory harm, though the pattern differs from tobacco. Regular cannabis smokers have higher rates of chronic bronchitis, increased respiratory symptoms (cough, wheeze, phlegm), and airway inflammation. However, unlike tobacco, cannabis smoking has not been consistently linked to COPD or lung cancer in epidemiological studies — possibly because cannabis users typically smoke fewer cigarettes per day than tobacco smokers. The carcinogen exposure per joint is higher than per cigarette, but total exposure is lower. Vaporization substantially reduces respiratory harm by eliminating combustion byproducts. A 2012 JAMA study found that moderate cannabis smoking (up to one joint per day for 7 years) was not associated with adverse lung function. Heavy use (>20 joint-years) was associated with decreased FEV1. Edibles and tinctures carry no respiratory risk.

Question 32

How does cannabis affect the developing adolescent brain?

Accepted Answer

The adolescent brain is uniquely vulnerable to cannabis because the endocannabinoid system plays a critical role in brain development through approximately age 25. CB1 receptors are more densely expressed in the adolescent brain than the adult brain, and the ECS guides synaptic pruning, myelination, and the maturation of prefrontal-limbic circuits. Regular cannabis use during adolescence is associated with: reduced gray matter volume in the hippocampus and prefrontal cortex; impaired working memory, attention, and executive function; earlier onset of psychosis in genetically susceptible individuals; higher rates of cannabis use disorder (17% vs. 9% for adult-onset users); and lower educational attainment. A key question is whether these effects are permanent or reversible with abstinence — evidence suggests some but not full recovery after extended abstinence.

Question 33

Is CBD safe for children?

Accepted Answer

CBD safety in children has been most rigorously studied in the context of epilepsy. Epidiolex (pharmaceutical-grade CBD) is FDA-approved for children aged 2+ with Dravet syndrome and Lennox-Gastaut syndrome, with a well-characterized safety profile in this population. Common side effects in pediatric epilepsy trials include somnolence, decreased appetite, diarrhea, and elevated liver enzymes (particularly when combined with valproate). For other pediatric conditions (anxiety, autism spectrum disorder, ADHD), evidence is limited to small open-label studies. The safety of consumer CBD products in children is unknown — these products are not regulated for purity, potency, or pediatric safety. Contamination with THC is a documented concern. No CBD product other than Epidiolex should be given to children without physician supervision.

Question 34

Does CBD help with athletic recovery and muscle soreness?

Accepted Answer

CBD is widely used by athletes for recovery, but clinical evidence is limited. Theoretically, CBD's anti-inflammatory and analgesic properties could reduce exercise-induced muscle damage and soreness. Preclinical studies show CBD reduces inflammatory markers after exercise in animal models. However, human RCT evidence is sparse. A 2021 randomized crossover trial found CBD did not significantly reduce muscle soreness or improve recovery markers after eccentric exercise in healthy adults. A 2020 study found no effect on cycling performance or perceived exertion. The World Anti-Doping Agency (WADA) removed CBD from its prohibited list in 2018, making it legal for competitive athletes. THC remains prohibited in-competition. The main practical concern for athletes is product contamination — many CBD products contain detectable THC that could trigger a positive drug test.

Question 35

Does cannabis enhance or impair athletic performance?

Accepted Answer

Cannabis does not enhance athletic performance and likely impairs it in most contexts. THC increases heart rate by 20–100% at rest, which may be detrimental for endurance sports. It impairs reaction time, coordination, and decision-making — critical for most sports. However, some athletes report cannabis reduces pre-competition anxiety and pain, potentially improving performance indirectly. A 2019 survey of 1,161 cannabis users found 81.7% used cannabis around exercise, primarily for enjoyment and recovery rather than performance enhancement. For pain management in contact sports, cannabis may allow athletes to train through injury — which raises safety concerns. The "runner's high" has been partially attributed to endocannabinoid release (anandamide), but exogenous THC does not replicate this effect and may blunt it.

Question 36

Is the entourage effect real? What does the science say?

Accepted Answer

The entourage effect — the hypothesis that whole-plant cannabis produces different effects than isolated cannabinoids due to synergistic interactions between cannabinoids, terpenes, and flavonoids — has theoretical support but limited clinical evidence. The concept was proposed by Raphael Mechoulam and Shimon Ben-Shabat in 1998. Preclinical evidence: terpenes like beta-caryophyllene (CB2 agonist), linalool (GABA-A modulator), and alpha-pinene (cholinesterase inhibitor) have pharmacological activity that could modulate cannabinoid effects. A 2020 study found that terpenes activate CB1 receptors and enhance cannabinoid-induced analgesia in mice. Clinical evidence: a 2018 retrospective study found whole-plant CBD extract more effective than purified CBD for epilepsy at lower doses, suggesting synergy. However, no well-designed RCT has directly tested the entourage effect in humans. The concept is widely accepted in the cannabis industry but remains scientifically unproven at the clinical level.

Question 37

What is beta-caryophyllene and what does it do?

Accepted Answer

Beta-caryophyllene (BCP) is a sesquiterpene found in cannabis, black pepper, cloves, and hops. It is unique among terpenes because it is a selective CB2 receptor agonist — making it technically a dietary cannabinoid. This CB2 agonism gives BCP anti-inflammatory, analgesic, and potentially neuroprotective properties without psychoactivity (CB2 receptors are primarily peripheral and immune-related, not central). Preclinical evidence: BCP reduces inflammatory pain in mouse models, protects against neuroinflammation, and shows anti-anxiety effects. A 2014 study found BCP reduced alcohol intake in mice by 50% via CB2 activation. Human evidence: limited to observational data and one small clinical study showing BCP-rich cannabis strains reduced anxiety more than BCP-poor strains. BCP is GRAS (Generally Recognized as Safe) by the FDA as a food flavoring.

Question 38

What does myrcene do in cannabis?

Accepted Answer

Myrcene is the most abundant terpene in most cannabis strains, typically comprising 20–65% of the terpene profile. It is also found in hops, mango, and lemongrass. Myrcene is widely claimed to produce sedative "couch-lock" effects and to enhance THC's psychoactivity by increasing blood-brain barrier permeability — but the evidence for both claims is weak. The sedative effects of myrcene in animal studies require doses far higher than those present in cannabis. The blood-brain barrier claim originates from a single 1997 study that has not been replicated. Myrcene does show analgesic and anti-inflammatory properties in preclinical models, acting via opioid receptors and TRPV1 channels. It is also a muscle relaxant in animal models. The popular claim that eating mango before cannabis enhances the high due to myrcene is not supported by pharmacokinetic evidence.

Question 39

What is the endocannabinoid system and why does it matter?

Accepted Answer

The endocannabinoid system (ECS) is a neuromodulatory system present in all vertebrates, discovered in the early 1990s through research on how THC works. It consists of: (1) Endogenous cannabinoids (endocannabinoids): anandamide (AEA) and 2-arachidonoylglycerol (2-AG), produced on-demand from cell membrane lipids; (2) Cannabinoid receptors: CB1 (primarily in the brain and CNS) and CB2 (primarily in immune cells and peripheral tissues); (3) Enzymes: FAAH (degrades anandamide) and MAGL (degrades 2-AG). The ECS regulates synaptic plasticity, pain, mood, appetite, memory, immune function, and stress response. It operates primarily through retrograde signaling — postsynaptic neurons release endocannabinoids that travel backward to inhibit presynaptic neurotransmitter release. This "dimmer switch" function explains why cannabinoids affect so many different physiological processes.

Question 40

What is anandamide and how does it relate to cannabis?

Accepted Answer

Anandamide (AEA) is an endogenous cannabinoid — a molecule produced naturally by the body that activates the same receptors as THC. Its name derives from the Sanskrit word "ananda" meaning bliss. Anandamide is synthesized on-demand from membrane phospholipids and rapidly degraded by the enzyme FAAH (fatty acid amide hydrolase). It activates CB1 receptors (with lower affinity than THC), TRPV1 channels, and GPR55. Anandamide is involved in pain modulation, mood regulation, memory, appetite, and the "runner's high" — a 2021 study found that exercise-induced euphoria in mice was blocked by CB1 antagonists, implicating anandamide. THC produces stronger, longer-lasting effects than anandamide because it is not degraded by FAAH and has higher CB1 affinity. FAAH inhibitors (which increase anandamide levels) are being developed as non-intoxicating anxiolytics.

Question 41

What is the difference between CB1 and CB2 receptors?

Accepted Answer

CB1 and CB2 are the two primary cannabinoid receptors, but they have distinct distributions and functions. CB1 receptors: predominantly expressed in the CNS — highest density in the basal ganglia, cerebellum, hippocampus, and prefrontal cortex. Also present in peripheral tissues including the liver, adipose tissue, and reproductive organs. CB1 activation by THC produces psychoactivity, analgesia, antiemesis, appetite stimulation, and memory impairment. CB2 receptors: predominantly expressed on immune cells (macrophages, T-cells, B-cells, microglia) and peripheral tissues. Minimal CNS expression under normal conditions, though expression increases during neuroinflammation. CB2 activation produces anti-inflammatory and immunomodulatory effects without psychoactivity. This distinction is clinically important: CB2-selective agonists (like beta-caryophyllene) may provide anti-inflammatory benefits without the psychoactive side effects of CB1 agonism.

Question 42

What is clinical endocannabinoid deficiency syndrome?

Accepted Answer

Clinical endocannabinoid deficiency (CED) is a theoretical condition proposed by Dr. Ethan Russo in 2004, suggesting that deficient endocannabinoid tone may underlie conditions including migraine, fibromyalgia, and irritable bowel syndrome. The hypothesis is based on: (1) the ECS regulates pain, gut motility, and mood — all affected in these conditions; (2) patients with migraine have lower CSF anandamide levels than controls; (3) these conditions share features of central sensitization and respond to treatments that enhance endocannabinoid tone. CED remains a hypothesis rather than a confirmed diagnosis — there is no validated biomarker, diagnostic test, or clinical criteria. It has not been formally recognized by any medical organization. However, it has generated research interest and provides a theoretical framework for why cannabis may help these conditions. Critics note it risks circular reasoning.

Question 43

How does cannabis affect the hippocampus and memory formation?

Accepted Answer

The hippocampus has one of the highest densities of CB1 receptors in the brain, concentrated on GABAergic interneurons and glutamatergic pyramidal cells. THC disrupts hippocampal function by impairing long-term potentiation (LTP) — the synaptic strengthening mechanism underlying memory encoding. Acutely, THC impairs encoding of new declarative memories (anterograde amnesia) while leaving retrieval of pre-existing memories largely intact. The mechanism involves CB1-mediated suppression of acetylcholine release in the hippocampus, disruption of theta oscillations (4–8Hz rhythms critical for memory encoding), and impairment of place cell firing patterns. Chronic heavy use is associated with reduced hippocampal volume (5–12% reduction in some studies), though this appears partially reversible with abstinence. CBD does not impair and may enhance hippocampal neurogenesis in animal models.

Question 44

Does cannabis affect dopamine and the brain's reward system?

Accepted Answer

Cannabis modulates the mesolimbic dopamine system — the brain's primary reward circuit — through indirect mechanisms. CB1 receptors on GABAergic interneurons in the ventral tegmental area (VTA) normally suppress dopamine neuron firing. THC activates these CB1 receptors, disinhibiting dopamine neurons and causing acute dopamine release in the nucleus accumbens. This is the neurochemical basis of cannabis's rewarding effects. However, unlike direct dopamine agonists (cocaine, amphetamine), the dopamine surge from cannabis is modest and indirect. Chronic heavy use is associated with blunted dopamine synthesis capacity and reduced D2/D3 receptor availability in the striatum — findings consistent with reward hyposensitivity and potentially explaining motivational deficits in heavy users. These changes appear to normalize with extended abstinence (weeks to months).

Question 45

Is CBD neuroprotective, and what are the mechanisms?

Accepted Answer

CBD has demonstrated neuroprotective effects across multiple preclinical models, with several plausible mechanisms: (1) Antioxidant activity — CBD is a potent antioxidant, scavenging reactive oxygen species that cause oxidative neuronal damage. (2) Anti-inflammatory effects — CBD reduces microglial activation and pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in the CNS. (3) Excitotoxicity protection — CBD modulates NMDA receptor activity and reduces glutamate-mediated excitotoxicity. (4) Mitochondrial protection — CBD stabilizes mitochondrial membrane potential. (5) Neurogenesis promotion — CBD enhances hippocampal neurogenesis via 5-HT1A receptor activation. Human evidence is limited to specific contexts: CBD (as Epidiolex) reduces neurological damage markers in neonatal hypoxic-ischemic encephalopathy models, and CBD shows promise in traumatic brain injury preclinical studies. Translation to adult human neuroprotection remains unproven in RCTs.

Question 46

How does cannabis affect the prefrontal cortex and executive function?

Accepted Answer

The prefrontal cortex (PFC) — responsible for planning, decision-making, impulse control, and working memory — is highly sensitive to cannabinoid modulation. CB1 receptors are densely expressed on PFC pyramidal neurons and interneurons. Acute THC disrupts PFC function by impairing dopamine-glutamate balance, reducing working memory capacity, slowing processing speed, and impairing inhibitory control. fMRI studies show altered PFC activation patterns during cognitive tasks after acute THC. In adolescents, whose PFC is still developing until age 25, chronic cannabis exposure is associated with structural changes (reduced gray matter volume, altered white matter integrity) and persistent cognitive deficits that may not fully resolve. In adults, acute PFC impairment resolves within hours; chronic effects are more modest and largely reversible with abstinence. The adolescent brain is substantially more vulnerable.

Question 47

What is the neurobiological mechanism linking cannabis to psychosis?

Accepted Answer

The cannabis-psychosis link involves multiple converging neurobiological pathways. Primary mechanism: THC disrupts striatal dopamine regulation by activating CB1 receptors on glutamatergic inputs to the striatum, causing excessive dopamine release — the same neurochemical signature seen in schizophrenia. Secondary: THC impairs prefrontal cortical regulation of subcortical dopamine, reducing top-down inhibitory control. Third: THC activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol, which sensitizes dopamine systems. Genetic vulnerability is critical — individuals with COMT Val158Met polymorphism, AKT1 variants, or family history of psychosis have substantially elevated risk. High-potency THC (>15%) and early onset use (before age 16) are the strongest environmental risk factors. CBD appears to counteract some of these effects by reducing striatal dopamine synthesis capacity.

Question 48

What does the evidence say about cannabis for PTSD?

Accepted Answer

PTSD is one of the most biologically plausible indications for cannabis, and the evidence is more promising than for most conditions — though still limited by study quality. The ECS rationale: PTSD patients show reduced CB1 receptor availability in the amygdala and anterior cingulate cortex, and lower anandamide levels — suggesting endocannabinoid deficiency in fear-processing circuits. THC may reduce nightmare frequency and severity by suppressing REM sleep and reducing amygdala hyperreactivity. A 2021 Canadian RCT (Jetly et al.) found nabilone (synthetic THC) significantly reduced nightmares vs. placebo. Observational studies consistently show patient-reported improvements in sleep, hyperarousal, and anxiety. However, concerns include: cannabis may impair fear extinction learning (critical for trauma therapy), may worsen dissociation in some patients, and long-term use carries addiction risk. Current evidence supports cautious use for nightmare reduction, not as a replacement for evidence-based psychotherapy.

Question 49

How effective is cannabis for multiple sclerosis symptoms?

Accepted Answer

MS is the indication with the strongest clinical evidence for cannabis, particularly for spasticity and neuropathic pain. Nabiximols (Sativex — 1:1 THC:CBD oromucosal spray) is approved in 30+ countries for MS spasticity. A 2012 Cochrane review of 12 RCTs found cannabinoids significantly reduced patient-reported spasticity (NRS) and pain, though objective spasticity measures (Ashworth scale) showed smaller effects. The 2014 MUSEC trial (n=279) found oral cannabis extract reduced muscle stiffness and pain vs. placebo. For bladder dysfunction (overactive bladder, nocturia) — a major MS symptom — nabiximols showed significant benefit in the CAMS trial. Limitations: most trials are short-term (≤12 weeks); long-term safety data in MS patients is limited; cognitive effects are a concern given existing MS-related cognitive impairment.

Question 50

Can cannabis help inflammatory bowel disease and Crohn's disease?

Accepted Answer

The GI tract has one of the highest densities of CB1 and CB2 receptors in the body, and the ECS plays a key role in regulating gut motility, inflammation, and intestinal permeability. This provides strong biological rationale for cannabis in IBD. Clinical evidence: A 2013 Israeli RCT (Naftali et al., n=21) found cannabis cigarettes induced clinical remission in 45% of Crohn's patients vs. 10% placebo — but did not reduce inflammatory markers (CRP, calprotectin), suggesting symptom relief without true anti-inflammatory effect. A 2021 follow-up RCT found similar results. For ulcerative colitis, a 2018 RCT found CBD capsules did not improve remission rates. Patient surveys consistently show high rates of self-reported symptom improvement (pain, nausea, appetite, stool frequency). The disconnect between symptom relief and objective inflammation reduction is a critical finding — cannabis may mask symptoms without treating underlying disease, potentially delaying effective treatment.

Question 51

Is there evidence for cannabis in fibromyalgia?

Accepted Answer

Fibromyalgia is characterized by central sensitization — amplified pain processing — and the ECS plays a key role in modulating central pain pathways, making it a theoretically strong indication. Clinical evidence is limited but growing. A 2019 Israeli observational study (n=367) found medical cannabis significantly reduced pain intensity (from 9/10 to 5/10 on NRS) and improved sleep and quality of life after 6 months. A 2020 RCT (van de Donk et al., n=20) found inhaled cannabis (both THC-dominant and CBD-dominant) reduced pain vs. placebo, with THC-dominant showing greatest effect. The fibromyalgia-ECS connection is supported by Ethan Russo's clinical endocannabinoid deficiency hypothesis — fibromyalgia patients show altered ECS tone. Limitations: most studies are observational; placebo-controlled trials are methodologically challenging; long-term data is absent.

Question 52

Does cannabis lower intraocular pressure in glaucoma?

Accepted Answer

Cannabis does lower intraocular pressure (IOP) — this is well-established. THC reduces IOP by 25–30% for 3–4 hours after smoking, comparable to some pharmaceutical agents. The mechanism involves CB1 receptors in the ciliary body reducing aqueous humor production, and vasodilation of ocular blood vessels. However, the American Academy of Ophthalmology does not recommend cannabis for glaucoma for several reasons: (1) Duration is too short — glaucoma requires 24-hour IOP control; cannabis would require dosing every 3–4 hours, including overnight. (2) Systemic side effects (cognitive impairment, cardiovascular effects) at the required frequency are unacceptable for a chronic condition. (3) Hypotension from cannabis may reduce ocular perfusion pressure, potentially worsening optic nerve damage despite lower IOP. (4) Tolerance develops rapidly. Topical cannabinoid formulations that avoid systemic effects are under investigation.

Question 53

How does cannabis stimulate appetite, and is it effective for cachexia?

Accepted Answer

THC stimulates appetite through CB1 receptor activation in the hypothalamus, particularly the arcuate nucleus, which regulates hunger hormones. Mechanisms include: enhanced olfactory sensitivity (food smells more appealing), increased ghrelin release, reduced leptin sensitivity, and activation of hypothalamic neurons that normally signal starvation. This is the basis of the "munchies." For cachexia (wasting syndrome in cancer and HIV/AIDS), dronabinol (synthetic THC) is FDA-approved. However, clinical trial results are mixed: a 2006 Cochrane review found dronabinol modestly improved appetite but not body weight or quality of life vs. placebo in cancer cachexia. Megestrol acetate (a progestational agent) outperformed dronabinol in a head-to-head trial. For HIV-associated wasting, evidence is somewhat stronger. The appetite-stimulating effect is more consistent than the weight-gain effect.

Question 54

How effective is cannabis for chemotherapy-induced nausea and vomiting?

Accepted Answer

This is one of the best-supported indications for cannabinoids. The brainstem dorsal vagal complex and nucleus tractus solitarius — key emesis control centers — express CB1 receptors that, when activated, suppress vomiting. Dronabinol and nabilone are FDA-approved for chemotherapy-induced nausea and vomiting (CINV) refractory to standard antiemetics. A 2001 Cochrane review of 30 RCTs found cannabinoids superior to placebo and comparable to older antiemetics (prochlorperazine, metoclopramide) for CINV. However, modern 5-HT3 antagonists (ondansetron) and NK1 antagonists (aprepitant) are more effective and better tolerated than cannabinoids for most patients. Cannabinoids remain a useful option for refractory CINV or as add-on therapy. Smoked/vaporized cannabis has not been studied in controlled CINV trials — only pharmaceutical cannabinoids have RCT evidence.

Question 55

Do THC and CBD work better together than alone?

Accepted Answer

The interaction between THC and CBD is complex and context-dependent — not simply additive or synergistic. CBD modulates THC effects through several mechanisms: (1) CBD inhibits CYP2C9 and CYP3A4 enzymes that metabolize THC, increasing THC plasma levels — a pharmacokinetic interaction. (2) CBD acts as a negative allosteric modulator at CB1 receptors, reducing THC's maximal efficacy — potentially reducing psychoactive effects and anxiety. (3) CBD independently activates 5-HT1A, TRPV1, and GPR55 receptors, contributing its own therapeutic effects. Clinical evidence for synergy: the nabiximols (Sativex) 1:1 ratio was chosen partly based on evidence that CBD reduces THC-induced anxiety and cognitive impairment. A 2019 study found 1:1 THC:CBD produced less anxiety than THC alone. However, for some indications (pain, spasticity), THC-dominant preparations may be more effective. The "entourage effect" — broader synergy including terpenes and minor cannabinoids — has theoretical support but limited direct clinical evidence.

Question 56

How do different routes of cannabis administration compare pharmacologically?

Accepted Answer

Route of administration dramatically affects onset, peak, duration, and bioavailability: Inhalation (smoking/vaporizing): onset 1–3 minutes, peak 10–30 minutes, duration 2–4 hours, bioavailability 10–35% (highly variable). Rapid onset makes titration easier but also enables rapid intoxication. Oral (edibles, capsules): onset 30–120 minutes, peak 2–4 hours, duration 6–12 hours, bioavailability 4–20%. THC undergoes extensive first-pass hepatic metabolism to 11-OH-THC (more potent, longer-acting than THC) — explaining why edibles feel qualitatively different. Sublingual (tinctures, nabiximols): onset 15–45 minutes, peak 1–2 hours, duration 4–8 hours, bioavailability 12–35%. Bypasses first-pass metabolism partially. Topical: minimal systemic absorption; local effects only. Transdermal patches: slow, consistent delivery; useful for chronic conditions. For clinical use, oral and sublingual routes are preferred for consistency; inhalation for acute symptom relief.

Question 57

Are there sex differences in how cannabis affects men and women?

Accepted Answer

Significant sex differences exist in cannabis pharmacology, largely driven by estrogen-mediated modulation of the ECS. Key findings: (1) Sensitivity: Women are more sensitive to THC's analgesic effects during high-estrogen phases of the menstrual cycle — estrogen upregulates CB1 receptor expression. (2) Tolerance: Women develop tolerance to THC's analgesic effects faster than men. (3) Addiction risk: Women progress from first use to cannabis use disorder faster than men ("telescoping effect"), despite typically using less cannabis. (4) Cognitive effects: Some studies show greater acute cognitive impairment in women. (5) Anxiety: Women report more anxiety and paranoia from THC at equivalent doses. (6) Withdrawal: Women report more severe withdrawal symptoms. These differences have important clinical implications — most cannabis research has been conducted predominantly in male subjects, limiting generalizability.

Question 58

How does cannabis affect older adults differently, and is it safe for seniors?

Accepted Answer

Cannabis use among adults 65+ is the fastest-growing demographic segment, driven by pain, sleep, and anxiety management. Older adults face distinct pharmacological considerations: (1) Pharmacokinetics: Reduced hepatic metabolism (lower CYP450 activity) increases THC plasma levels and duration. Increased body fat raises THC volume of distribution. (2) Sensitivity: Age-related CB1 receptor changes and reduced dopamine tone may alter effects. (3) Drug interactions: Polypharmacy is common in seniors — CBD inhibits CYP2C9 (warfarin), CYP3A4 (statins, calcium channel blockers), and CYP2D6 (antidepressants). (4) Falls risk: Cannabis impairs balance and coordination; falls are the leading cause of injury death in seniors. (5) Cardiovascular: Tachycardia from THC is more dangerous in patients with existing cardiac disease. A 2020 JAMA Internal Medicine study found cannabis use associated with increased falls and fractures in adults 65+. Start low, go slow is especially critical in this population.

Question 59

What are the pharmacological properties of CBG (cannabigerol)?

Accepted Answer

CBG (cannabigerol) is the biosynthetic precursor to THC, CBD, and CBC — often called the "mother cannabinoid." Its pharmacological profile is distinct from THC and CBD: Receptor activity: CBG is a partial agonist at CB1 (lower efficacy than THC, so less psychoactive) and CB2 receptors, an α2-adrenoceptor agonist, a 5-HT1A antagonist, and a TRPV1 agonist. Anti-inflammatory: CBG inhibits COX-1 and COX-2 enzymes and reduces pro-inflammatory cytokines — potentially relevant for IBD and neuroinflammation. Antibacterial: CBG shows potent activity against MRSA and other drug-resistant bacteria in vitro. Neuroprotective: CBG protected neurons in a Huntington's disease mouse model. Appetite stimulation: CBG stimulated appetite in rats without THC-like psychoactivity. Limitations: virtually all CBG research is preclinical; no human RCTs exist. Commercial interest has outpaced the science significantly.

Question 60

Does CBN (cannabinol) actually cause sedation? What does the evidence show?

Accepted Answer

CBN is widely marketed as a sleep aid, but the evidence for sedation is remarkably thin. CBN is a THC degradation product formed by oxidation — aged cannabis has higher CBN content. The sedation claim originates largely from a 1975 study (Karniol et al.) that found CBN enhanced THC-induced sedation — but this was CBN combined with THC, not CBN alone. A 2021 Steep Hill Labs study (unpublished, industry-funded) claimed CBN was sedating, but this has not been replicated in peer-reviewed research. CBN's receptor pharmacology: weak partial CB1 agonist (10x less potent than THC), CB2 agonist, TRPV2 agonist. None of these mechanisms strongly predict sedation. A 2023 review in Sleep Medicine Reviews concluded there is insufficient evidence to support CBN as a sleep aid. The sedation effect in aged cannabis may be due to terpene degradation products, not CBN itself. This is a case where marketing has substantially outpaced science.

Question 61

What are the unique properties of THCV (tetrahydrocannabivarin)?

Accepted Answer

THCV has a pharmacological profile that is in some ways opposite to THC, making it scientifically interesting. At low doses, THCV acts as a CB1 antagonist — blocking THC's effects and potentially reducing appetite (anti-obesity effect). At high doses, THCV becomes a CB1 partial agonist with mild psychoactive effects. CB2 agonism: THCV is a potent CB2 agonist, with potential anti-inflammatory applications. Metabolic effects: THCV improved glycemic control and reduced fasting glucose in a 2016 RCT in type 2 diabetes patients (Jadoon et al., Diabetes Care) — the only cannabinoid RCT in diabetes. Anticonvulsant: THCV shows anticonvulsant properties in animal models. Neuroprotective: THCV protected dopaminergic neurons in Parkinson's disease models. The appetite-suppressing effect (vs. THC's appetite stimulation) and metabolic benefits make THCV a candidate for obesity and metabolic syndrome research. Commercial THCV products exist but clinical evidence beyond the diabetes RCT is absent.

Question 62

What are the acute cardiovascular effects of cannabis?

Accepted Answer

Cannabis produces significant acute cardiovascular effects, primarily mediated by THC. Tachycardia: THC causes dose-dependent heart rate increases of 20–100% above baseline, peaking at 10–30 minutes and lasting 2–3 hours. Mechanism: sympathetic activation and vagal inhibition via CB1 receptors. Blood pressure: biphasic response — initial increase followed by orthostatic hypotension (particularly with standing). Cardiac output increases acutely. Clinical risks: In healthy young adults, these effects are generally well-tolerated. In patients with coronary artery disease, the increased cardiac workload (heart rate × blood pressure) can precipitate angina or myocardial infarction. A 2001 study (Mittleman et al.) found cannabis use increased MI risk 4.8-fold in the hour after use. Arrhythmias: case reports of atrial fibrillation, ventricular tachycardia, and Takotsubo cardiomyopathy associated with acute cannabis use. Risk is substantially higher in older adults and those with pre-existing cardiac disease.

Question 63

Is vaping cannabis safer than smoking for lung health?

Accepted Answer

Vaporization is generally considered less harmful than combustion for lung health, but "safer" does not mean "safe." Combustion produces carbon monoxide, tar, and numerous carcinogens from pyrolysis — all absent with vaporization. Studies show vaporizers produce fewer respiratory toxicants than smoking. A 2010 RCT (Abrams et al.) found vaporization produced equivalent cannabinoid delivery with lower carbon monoxide exposure. However, vaping carries its own risks: (1) EVALI (e-cigarette or vaping product use-associated lung injury) — the 2019 outbreak was linked primarily to vitamin E acetate in illicit THC cartridges, not licensed cannabis products, but illustrates the risk of adulterants. (2) Lipid pneumonia risk from oil-based cartridges. (3) Thermal degradation products at high temperatures (>230°C). (4) Heavy metal contamination from heating elements in low-quality devices. For patients who choose inhalation, vaporization of flower at 170–185°C appears to be the lowest-risk option. No inhalation route is without risk.

Question 64

Can CBD or cannabis cause liver damage?

Accepted Answer

Hepatotoxicity is a real concern with high-dose CBD, established through clinical trial data. In Epidiolex trials, liver enzyme elevations (ALT/AST >3x upper limit of normal) occurred in 5–20% of patients on high doses (20mg/kg/day), with 3 cases of serious hepatotoxicity. Risk factors: concomitant valproate use (dramatically increases risk), high CBD doses, and pre-existing liver disease. Mechanism: likely CYP450 enzyme inhibition causing drug-drug interactions, plus possible direct hepatotoxic effects. At lower doses (typical supplement doses of 10–100mg/day), liver enzyme elevations are rare in clinical studies. THC: less evidence for direct hepatotoxicity, but cannabis use is associated with accelerated fibrosis progression in patients with pre-existing hepatitis C. Practical guidance: patients on hepatotoxic medications (valproate, methotrexate, statins) should have liver function monitored if using high-dose CBD. Commercial CBD supplements at typical doses appear low-risk for liver injury in healthy individuals.

Ask a Researcher

100 Questions